Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: The role of glutathione S-transferase P1-1

Clinical Cancer Research

Volumn 18, Issue 24, 2012, Pages 6690-6701

  Wang, Rui ^a   Liu, Changda ^a   Xia, Lijuan ^a   Zhao, Guisen ^b   Gabrilove, Janice ^a   Waxman, Samuel ^a   Jing, Yongkui ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CASPASE 9; CYTOCHROME C; ENZYME INHIBITOR; ETACRYNIC ACID; ETACRYNIC ACID BUTYL ESTER; GLUTATHIONE; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE P1 1; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENE SILENCING; GSTP1 GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOMA; LYMPHOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOTHERAPY; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CASPASES; CATALASE; CELL LINE, TUMOR; DRUG SYNERGISM; ENZYME ACTIVATION; ETHACRYNIC ACID; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LEUKEMIA, MYELOID; LYMPHOMA; MAP KINASE KINASE 4; MEMBRANE POTENTIAL, MITOCHONDRIAL; OXIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84871195298     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0770     Document Type: Article

References (46)

1. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-24. (Pubitemid 29536124)
2. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60. (Pubitemid 32880064)
3. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001;97:264-9. (Pubitemid 32061269)
4. Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 2003;63:1853-9. (Pubitemid 36460848)
5. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-77. (Pubitemid 29019412)
6. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102-11. (Pubitemid 29430427)
7. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998;90:124-33. (Pubitemid 28114413)
8. Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A 2004;101:4578-83. (Pubitemid 38437453)
9. Zhou L, Jing Y, Styblo M, Chen Z, Waxman S. Glutathione-S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood 2005;105:1198-203. (Pubitemid 40170894)
10. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903. (Pubitemid 34792653)
11. Wang Z, Dey S, Rosen BP, Rossman TG. Efflux-mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Toxicol Appl Pharmacol 1996;137:112-9. (Pubitemid 26095864)
12. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, et al. Regulation of JNK signaling by GSTp. EMBO J 1999;18:1321-34. (Pubitemid 29110316)
13. Wang T, Arifoglu P, Ronai Z, Tew KD. Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 2001;276:20999-1003.
14. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999;91:772-8. (Pubitemid 29239056)
15. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998;12:1383-91. (Pubitemid 28442384)
16. Ploemen JH, van Ommen B, van Bladeren PJ. Inhibition of rat and human glutathione S-transferase isoenzymes by ethacrynic acid and its glutathione conjugate. Biochem Pharmacol 1990;40:1631-5. (Pubitemid 20310584)
17. Aizawa S, Ookawa K, Kudo T, Asano J, Hayakari M, Tsuchida S. Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci 2003;94:886-93. (Pubitemid 37406971)
18. Wang R, Li C, Song D, Zhao G, Zhao L, Jing Y. Ethacrynic acid butyl-ester induces apoptosis in leukemia cells through a hydrogen peroxide mediated pathway independent of glutathione S-transferase P1-1 inhibition. Cancer Res 2007;67:7856-64. (Pubitemid 47281381)
19. Yamada M, Hashinaka K, Inazawa J, Abe T. Expression of catalase and myeloperoxidase genes in hydrogen peroxide-resistant HL-60 cells. DNA Cell Biol 1991;10:735-42.
20. Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A 2007;104:3207-12. (Pubitemid 46364138)
21. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
22. Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995;182:367-77.
23. Wang R, Xia L, Gabrilove J, Waxman S, Jing Y. Downregulation of Mcl-1 through GSK-3beta activation contributes to arsenic trioxideinduced apoptosis in acute myeloid leukemia cells. Leukemia. 2012 Jul 3. [Epub ahead of print].
24. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000;191:977-84.
25. Liu Q, Zhang H, Smeester L, Zou F, Kesic M, Jaspers I, et al. The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics 2010;3:37.
26. Morales AA, Gutman D, Cejas PJ, Lee KP, Boise LH. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. J Biol Chem 2009;284:12886-95.
27. Kasugai I, Yamada M. High production of catalase in hydrogen peroxide-resistant human leukemia HL-60 cell lines. Leuk Res 1992;16:173-9.
28. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005;120:649-61. (Pubitemid 40343077)
29. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001;98:13681-6. (Pubitemid 33115958)
30. Bernardini S, Nuccetelli M, Noguera NI, Bellincampi L, Lunghi P, Bonati A, et al. Role of GSTP1-1 in mediating the effect of As2O3 in the acute promyelocytic leukemia cell line NB4. Ann Hematol 2006;85:681-7. (Pubitemid 44255038)
31. Mann KK, Colombo M, Miller WH Jr. Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol Cancer Ther 2008;7:1680-7.
32. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006;21:749-60. (Pubitemid 43376126)
33. Sanchez-Perez T, Ortiz-Ferron G, Lopez-Rivas A. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ 2010;17:883-94.
34. Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J, et al. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 2002;277:43730-4. (Pubitemid 36157790)
35. Schimmer AD, Dalili S. Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. Hematology Am Soc Hematol Educ Program 2005:215-9.
36. Awasthi S, Srivastava SK, Ahmad F, Ahmad H, Ansari GA. Interactions of glutathione S-transferase-piwith ethacrynic acid and its glutathione conjugate. Biochim Biophys Acta 1993;1164:173-8. (Pubitemid 23211010)
37. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003;17:931-40. (Pubitemid 36626322)
38. Chen D, Chan R, Waxman S, Jing Y. Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and upregulation of death receptors. Cancer Res 2006;66:11416-23. (Pubitemid 46009973)
39. O'Dwyer PJ, LaCreta F, Nash S, Tinsley PW, Schilder R, Clapper ML, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 1991;51:6059-65.
40. Lacreta FP, Brennan JM, Nash SL, Comis RL, Tew KD, O'Dwyer PJ. Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther 1994;270:1186-91. (Pubitemid 24315238)
41. Zhao G, Yu T, Wang R, Wang X, Jing Y. Synthesis and structure-activity relationship of ethacrynic acid analogues on glutathione-s-transferase P1-1 activity inhibition. Bioorg Med Chem 2005;13:4056-62. (Pubitemid 40725037)
42. Thieblemont C, Rolland D, Baseggio L, Felman P, Gazzo S, Callet-Bauchu E, et al. Comprehensive analysis of GST-pi expression in B-cell lymphomas: correlation with histological subtypes and survival. Leuk Lymphoma 2008;49:1403-6. (Pubitemid 352015806)
43. Bennaceur-Griscelli A, Bosq J, Koscielny S, Lefrere F, Turhan A, Brousse N, et al. High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res 2004;10:3029-34. (Pubitemid 38619679)
44. Borde-Chiche P, Diederich M, Morceau F, Puga A, Wellman M, Dicato M. Regulation of transcription of the glutathione S-transferase P1 gene by methylation of the minimal promoter in human leukemia cells. Biochem Pharmacol 2001;61:605-12. (Pubitemid 32178495)
45. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998;58:4515-8. (Pubitemid 28480605)
46. Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, et al. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 2004;89:154-64. (Pubitemid 38796489)